title: Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.
authors.affiliation: Corresponding author: Lotte Bjerre Knudsen, lbkn@novonordisk.com.
authors.forename: Lotte Bjerre
authors.initials: LB
authors.lastname: Knudsen
authors.forename: Niels C Berg
authors.initials: NC
authors.lastname: Nyborg
authors.forename: Claus Bo
authors.initials: CB
authors.lastname: Svendsen
authors.forename: Niels
authors.initials: N
authors.lastname: Vrang
authors.forename: Alan C
authors.initials: AC
authors.lastname: Moses
mesh_terms: D000818:Animals; D006801:Humans; D054795:Incretins / Q000627:therapeutic use*
chemical_list: D054795:Incretins